New study shows rise in drug resistance of dangerous infection in US hospitals

December 23, 2009

A new study in the journal Infection Control and Hospital Epidemiology reports a surge in drug-resistant strains of Acinetobacter, a dangerous type of bacteria that is becoming increasingly common in U.S. hospitals. This study is being posted online today and will appear in the journal's February print edition.

Acinetobacter infections attack patients in hospital intensive care units (ICUs) and others and have recently plagued soldiers returning home from the war in Iraq. These infections often appear as severe pneumonias or bloodstream infections, and require strong drugs to be treated, when they can be stopped at all.

Using data from 300 hospitals around the country, researchers at the Extending the Cure project analyzed trends in resistance to imipenem, an antibiotic often reserved as a last-line treatment. The study found that between 1999 and 2006, there was more than a 300% increase in the proportion of Acinetobacter cases resistant to the drug. Extending the Cure is supported by the Robert Wood Johnson Foundation's Pioneer Portfolio, which funds innovative ideas that may lead to breakthroughs in the future of health and health care.

"The findings are troubling because they suggest this bacteria is becoming resistant to nearly everything in our arsenal," said Ramanan Laxminarayan, the principal investigator of Extending the Cure, a project examining at the Washington, D.C. based think-tank Resources for the Future. "There is a lot of attention on MRSA, but less on infections caused by bacteria like Acinetobacter for which there are fewer drugs in the development pipeline. While all is of concern, it is particularly worrying in the case of bugs for which we have few treatment options."

To address this growing public health threat, the nation must adopt a comprehensive solution to the problem of antibiotic resistance, the researchers said. For example, we should institute more rigorous infection control on a regional basis. In addition, drug companies must be given incentives to develop novel antibiotics that can destroy these , according to authors.

Related Stories

Recommended for you

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Dec 24, 2009
I've been speaking out to everyone from the courthouse to the White House and there's no one who can do anything about MRSA. We've avoided and shoved it under a rug for too long and soon we will be discussing VRE.

How many more innocent people and children have to die before we demand the filthy, greedy health care system clean up it's act ?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.